Racura Oncology Ltd (FRA:FN3)

Market Cap	264.43M +131.7%
Revenue (ttm)	2.07M -43.3%
Net Income	-6.71M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.290
Previous Close	1.240
Day's Range	1.280 - 1.290
52-Week Range	0.640 - 2.640
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Racura Oncology

Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-s...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: FN3

Financial Performance

In fiscal year 2026, Racura Oncology's revenue was 2.81 million, a decrease of -46.49% compared to the previous year's 5.25 million. Losses were -11.09 million, 131.6% more than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error